| 方 晶,朱 远.尼妥珠单抗联合放疗的临床研究进展[J].中国肿瘤,2014,23(3):228-233. |
| 尼妥珠单抗联合放疗的临床研究进展 |
| Clinical Research Progress in Nimotuzumab Combination with Radiotherapy |
| 投稿时间：2013-06-01 |
| DOI：10.11735/j.issn.1004-0242.2014.03.A012 |
|
 |
| 中文关键词: 尼妥珠单抗 表皮生长因子受体 放射疗法 |
| 英文关键词:nimotuzumab epidermal growth factor receptor radiotherapy |
| 基金项目: |
|
| 摘要点击次数: 1697 |
| 全文下载次数: 897 |
| 中文摘要: |
| 摘 要：表皮生长因子受体（epidermal growth factor receptor，EGFR）在多种肿瘤中存在高表达，与肿瘤的进展、耐放化疗有关。抑制EGFR信号传导通路可控制肿瘤的发展。尼妥珠单抗作为一种新型的抗EGFR单克隆抗体，已应用于多种恶性肿瘤中。全文就尼妥珠单抗联合放疗在肿瘤治疗中的相关临床研究作一综述。 |
| 英文摘要: |
| Abstract：Epidermal growth factor receptor(EGFR) has overexpressed in many tumors，associating with tumor progression and resistances to radiation and chemotherapy. Inhibition of EGFR signaling pathway can control tumor development. Nimotuzumab is a new kind of EGFR monoclonal antibody，has been applied in a variety of malignant tumors. The relevant clinical researches about nimotuzumab combined radiotherapy are reviewed in this article. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |